Does Medicare Cover a CGM (Continuous Glucose Monitor)? (2026)

Direct Answer: Medicare CGM Coverage in 2026

Yes. Medicare Part B covers continuous glucose monitors (CGM) as durable medical equipment for beneficiaries with diabetes who use insulin or who have a documented history of problematic hypoglycemia. Covered brands include Dexcom G6, Dexcom G7, FreeStyle Libre 2, FreeStyle Libre 3, and the Eversense implantable sensor. You pay 20% of the Medicare-approved amount after the 2026 Part B deductible of $283, and Medicare Advantage plans must match this coverage at minimum.

What Original Medicare Part B Covers for CGMs

Original Medicare classifies a therapeutic CGM system as durable medical equipment rather than a prescription drug, so the receiver, transmitter, and sensors are billed under Part B, not Medicare Part D, the pharmacy benefit that covers insulin filled at a retail pharmacy. Part B pays 80% of the Medicare-approved amount once the 2026 Part B deductible of $283 is met, and the standard Part B premium in 2026 is $202.90 per month. Medicare Part A plays no role in outpatient CGM supplies; its diabetes benefit is limited to self-management training furnished during an inpatient hospital stay.

Medicare requires a therapeutic CGM, meaning the device is approved to make treatment decisions such as dosing insulin or adjusting food intake without a confirmatory fingerstick test. Dexcom G6, Dexcom G7, FreeStyle Libre 2, FreeStyle Libre 3, and the Eversense implantable CGM all meet this therapeutic standard and are covered nationwide when the durable medical equipment supplier is enrolled in Medicare and bills correctly.

Dexcom vs FreeStyle Libre vs Eversense: Brand-Specific Medicare Rules

Medicare's diabetes eligibility rules apply the same to every therapeutic CGM brand, but each device has its own hardware requirement tied to the standalone receiver rule: Medicare only pays for CGM supplies when the system can display glucose readings on a stand-alone receiver or an insulin pump classified as durable medical equipment, not solely on a smartphone or tablet.

Medicare's Two-Pathway CGM Eligibility Test

CMS finalized a major eligibility expansión effective April 16, 2023 that removed the old requirement of multiple daily insulin injections. Two pathways now qualify a beneficiary for CGM coverage in 2026. Pathway one covers anyone treated with insulin, regardless of type or how much they take, including basal-only insulin users. Pathway two covers beneficiaries not on insulin who have a documented history of problematic hypoglycemia, defined as more than one Level 2 hypoglycemic event, meaning glucose under 54 mg/dL, despite treatment changes, or one Level 3 event severe enough to require third-party assistance.

Documentation matters as much as the medical facts. Your treating practitioner must have seen you in person or through a Medicare-approved telehealth visit within the 6 months before ordering the CGM, and must record in your chart that you have diabetes, meet one of the two pathways above, and have received training on using the device correctly. Every 6 months after that, a follow-up visit is required to justify continued coverage, so a missed appointment is one of the most common causes of a coverage lapse.

What Medicare Advantage May Add for CGM Coverage (2026)

Medicare Advantage plans must cover CGMs to at least the same standard as Original Medicare, since Part C plans cannot offer less than Part A and Part B combined. Many Medicare Advantage plans go further in 2026 by waiving the 20% coinsurance entirely for in-network durable medical equipment suppliers, offering $0 copay CGM supplies as a supplemental benefit, or bundling CGM management into a broader diabetes care program with a nurse care coordinator. Some plans add prior authorization steps Original Medicare does not require, so checking your plan's Evidence of Coverage before ordering avoids a surprise denial.

Cost of a CGM Without Medicare Coverage in 2026

Full retail pricing in 2026 runs about $350 per month for Dexcom G7, roughly $175 per sensor box, and about $70 per month for FreeStyle Libre 3, roughly $35 per sensor, before any manufacturer discount. Beneficiaries who do not yet meet either 2026 eligibility pathway, or who want backup sensors between Medicare-covered supply shipments, often pay these cash-pay rates directly to the manufacturer or pharmacy.

Manufacturer savings programs cut those cash prices substantially in 2026. Dexcom's Simple Start program prices G7 supplies as low as $89 per month for uninsured patients, and Abbott's MyFreeStyle savings program lowers Libre 3 cash pricing for patients who do not have Medicare or other insurance covering the device. Neither program is insurance, and neither one counts toward the 2026 Part B deductible or your Medicare plan's annual out-of-pocket costs.

How to Get a CGM Approved, Plus Medicaid and ACA Coverage

Getting a CGM ordered through Medicare starts with confirming you meet one of the two eligibility pathways, then scheduling the required practitioner visit before your DME supplier submits the order. About 12 million Americans are dual-eligible for Medicare and Medicaid; for these beneficiaries, Medicare Part B pays first at 80% of the approved amount and Medicaid typically covers the remaining 20% coinsurance and the Part B deductible, so most dual-eligible beneficiaries pay nothing out of pocket for a Medicare-covered CGM.

Beneficiaries not yet on Medicare can look to the ACA marketplace, where diabetes management devices fall under the essential health benefits category for rehabilitative and habilitative devices, so ACA-compliant plans generally must cover CGMs when medically necessary, and cannot deny coverage based on a preexisting condition such as diabetes. If you are approaching age 65, coordinate the switch from marketplace coverage to Medicare during your Initial Enrollment Period to avoid a coverage gap for your CGM supplies.

Does Original Medicare cover the Dexcom G7?

Yes. Original Medicare Part B covers the Dexcom G7 as durable medical equipment for beneficiaries who use insulin or have a documented history of problematic hypoglycemia. You pay 20% of the Medicare-approved amount after the 2026 Part B deductible of $283. The G6 and G7 both require a compatible standalone receiver on file with your supplier; smartphone-only use is not billable to Medicare.

Does Medicare cover FreeStyle Libre 2 or Libre 3?

Yes. Medicare Part B covers FreeStyle Libre 2 and Libre 3 for beneficiaries meeting the insulin-use or problematic-hypoglycemia eligibility pathway. The Libre reader device satisfies Medicare's standalone-receiver requirement, so you can use the reader alongside the LibreLink phone app without a separate receiver purchase, unlike some Dexcom setups.

What are Medicare's CGM eligibility rules in 2026?

You qualify if you have diabetes and either use insulin, any type or amount, or have a documented history of problematic hypoglycemia, defined as more than one Level 2 event, glucose under 54 mg/dL, or one Level 3 event requiring third-party assistance. Your practitioner must also see you within 6 months before ordering the CGM and document your training on the device.

Does Medicare Advantage cover CGMs?

Yes. Medicare Advantage plans must cover CGMs at least as well as Original Medicare, and many 2026 plans offer $0 copay CGM supplies through in-network durable medical equipment suppliers as an added benefit. Some Medicare Advantage plans add prior authorization steps Original Medicare does not require, so check your plan's Evidence of Coverage before ordering.

How much does a CGM cost without Medicare coverage in 2026?

Full retail runs about $350 per month for Dexcom G7 and about $70 per month for FreeStyle Libre 3 in 2026. Manufacturer savings programs lower cash pricing substantially: Dexcom's Simple Start program prices G7 supplies as low as $89 per month for uninsured patients, and Abbott's MyFreeStyle program discounts Libre 3 for patients without CGM insurance coverage.

Does Medicare cover the Eversense implantable CGM?

Yes, when you meet the same insulin-use or problematic-hypoglycemia eligibility pathway required for Dexcom and FreeStyle Libre. The Eversense E3 sensor lasts 180 days and requires an in-office insertion and removal procedure, and its transmitter and smart transmitter combination satisfies Medicare's durable medical equipment classification.

Can I use a smartphone-only CGM setup with Medicare?

Not for billing purposes. Medicare requires the CGM system to display readings on a standalone receiver or an insulin pump classified as durable medical equipment. Dexcom G6 and G7 supplies are not covered when used only with a smartphone app; the compatible standalone receiver must be on file even if you check readings mostly on your phone.

What if Medicare denies my CGM claim?

Most CGM denials trace back to missing documentation: no record of insulin use or problematic hypoglycemia, no practitioner visit within 6 months of the order, or no standalone receiver on file. Ask your practitioner to resubmit with complete documentation, or file a Medicare appeal within 120 days of the denial notice.